Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to find out which of 4 different doses of minocycline are
safe and well tolerated so that we will know the optimal dose to test in future patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
David Hess, MD
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) Oregon Health and Science University University of Kentucky